Replimune's Q3 net loss widens as R&D expenses rise

Replimune

03/02/2026 13:10

Overview

Biotechnology firm's fiscal Q3 net loss was $70.9 mln vs $66.3 mln a year ago

Company preparing for RP1 launch, pending FDA approval

Loan agreement amended to extend cash runway into Q1 2027

Outlook

Replimune expects FDA decision on RP1 by April 10, 2026

Company extends cash runway into Q1 2027

RP2 Phase 2/3 transition expected in Q1 2027

Result Drivers

R&D EXPENSES - Increase in R&D expenses due to IGNYTE-3 study and RP1 launch preparations

CASH POSITION - Decrease in cash due to operating activities for clinical development

LOAN AGREEMENT - Amended loan agreement extends cash runway into Q1 2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$70.93 mln
Q3 Basic EPS
-$0.77
Q3 Cash & Investments
$269.10 mln
Q3 Operating Expenses
$71.87 mln
Q3 Operating Income
-$71.87 mln
Q3 Pretax Profit
-$71.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Replimune Group Inc is $12.00, about 72% above its February 2 closing price of $6.98

Press Release: ID:nGNX57Lk7D

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)